SCHEMBL2964228

SCHEMBL2964228

CCCc1ccc2c(Nc3cc(C(F)(F)F)ccc3-c3ccccc3)ccnc2n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNC P24863 1/20 0.41
CDK8 P49336 1/20 0.41
TRPV1 Q8NER1 8/20 0.40
ABCG2 Q9UNQ0 1/20 0.38
MAPK3 P27361 1/20 0.38
CYP19A1 P11511 1/20 0.36
CYP11B1 P15538 1/20 0.36
CYP11B2 P19099 1/20 0.36
CTSS P25774 1/20 0.36
CTSK P43235 1/20 0.36
SREBF2 Q12772 1/20 0.36
RIPK2 O43353 1/20 0.36
KDR P35968 1/20 0.36
MAPK14 Q16539 1/20 0.36
FABP4 P15090 1/20 0.35
GAK O14976 1/20 0.35
CYP2D6 P10635 1/20 0.35
PSEN1 P49768 1/20 0.35
PSEN2 P49810 1/20 0.35
APH1B Q8WW43 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2960501 0.85 SREBF2 (0.38) SREBF2
SCHEMBL2970962 0.79 SREBF2 (0.38) SREBF2
SCHEMBL2973903 0.73 SREBF2 (0.41) TRPV1SREBF2KDRCYP2D6PSEN1
SCHEMBL17613404 0.70 IDO1 (0.39) SREBF2
SCHEMBL2968656 0.69 MEN1 (0.36) KDR
SCHEMBL2961431 0.69 PIM1 (0.36) SREBF2
SCHEMBL15268008 0.69 KDM4E (0.37) SREBF2
SCHEMBL2968662 0.68 ALK (0.39) CCNCCDK8SREBF2RIPK2KDR
SCHEMBL2968446 0.67 PTK6 (0.54) ABCG2CYP2D6
SCHEMBL13230482 0.66 SREBF2 (0.42) SREBF2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338605-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2012-12-25 US disclosed
US-20100256139-A1 Anti-Viral Compounds ABBOTT LABORATORIES (US) 2010-10-07 US disclosed
EP-1979349-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2010-07-28 EP disclosed
US-7763731-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2010-07-27 US disclosed
EP-1979349-A2 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2008-10-15 EP disclosed
US-20070232645-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-10-04 US disclosed
WO-2007076035-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232645-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 CCNC 101/4885CDK8 160/4885TRPV1 3812/4885
US-20100256139-A1 Anti-Viral Compounds HAVCR2, MAVS, EIF2AK2 CCNC 101/4885CDK8 160/4885TRPV1 3812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.